Research Site s.r.o.

The trials here

What the 8 trials at this site are about, from their registry records.

Conditions

• Primary biliary cholangitis5 trials
• Fatty liver disease (MASLD/MASH)3 trials
• Liver cirrhosis1 trial

Phase

• Phase 37 trials
• Phase 21 trial

Status

• Recruiting5 trials
• Completed3 trials

Lead sponsor

• Boehringer Ingelheim2 trials
• Intercept Pharmaceuticals Inc.2 trials
• Ipsen2 trials
• Gilead Sciences1 trial
• Hoffmann-La Roche1 trial

Running trials

• Recruiting

  LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis

  NCT06632457· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced Liver Fibrosis

  NCT06632444· Phase 3· Boehringer Ingelheim· Source

• Recruiting

  A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

  NCT06318169· Phase 3· Hoffmann-La Roche· Source

• Recruiting

  Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis

  NCT06051617· Phase 3· Gilead Sciences· Source

• Recruiting

  A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis

  NCT06016842· Phase 3· Ipsen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Fatty liver disease (MASLD/MASH)3 recruiting
• Primary biliary cholangitis2 recruiting
• Liver cirrhosis1 recruiting

Closed trials

• Completed

  A Phase 3, Open-Label, Long-Term Safety Extension Study Evaluating the Safety and Tolerability of the Fixed-Dose Combination of Obeticholic Acid and Bezafibrate in Subjects with Primary Biliary Cholangitis

  2023-507771-22-01· Phase 3· Intercept Pharmaceuticals Inc.· Source

• Completed

  A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.

  NCT06383403· Phase 3· Ipsen· Source

• Completed

  A study to learn about the effects and safety of obeticholic acid in combination with bezafibrate in participants with primary biliary cholangitis.

  NCT04594694· Phase 2· Intercept Pharmaceuticals Inc.· Source